IMEIK(SZ:300896) Cai Jing Wang·2025-08-19 04:46Core Insights - The company reported a 21.59% decline in revenue for the first half of 2025, totaling 1.299 billion yuan, while net profit attributable to shareholders decreased by 29.57% to 789 million yuan [1] Group 1: Financial Performance - Revenue for the first half of 2025 was 1.299 billion yuan, reflecting a 21.59% decrease compared to the previous period [1] - Net profit attributable to shareholders was 789 million yuan, down 29.57% year-on-year [1] Group 2: Strategic Initiatives - The company is strategically investing in overseas markets to enhance its core competitiveness [1] - A major investment included the acquisition of 85% of South Korea's REGEN company for 190 million USD [1] Group 3: Product Development - REGEN, established in 2000, is the first in South Korea and the third globally to obtain registration for polylactic acid-based dermal fillers [1] - The products AestheFill and PowerFill, which contain PDLLA microspheres and sodium carboxymethyl cellulose, have received regulatory approval in 35 and 23 countries respectively [1] - A new product, "Medical Polyvinyl Alcohol Gel Microsphere Cross-linked Sodium Hyaluronate Gel" (brand name: Gakela), was launched in May for treating mild to moderate chin retrusion [1]